Albany, NY -- (SBWIRE) -- 08/26/2019 -- Cardiotoxicity Market Insights, Epidemiology and Market Forecast-2028
1. Cardiotoxicity occurred in 9% of a mixed group of 2625 adult patients (aged 50 ± 13 years, 51% breast cancer, 28% Hodgkin lymphoma, 74% women) followed up for a median period of 5.2 years.
2. More than 50% of 270,000 childhood cancer survivors in the United States have been treated with anthracyclines, and are, therefore, at risk of developing cardiotoxicity.
DelveInsight launched a new report on Cardiotoxicity Market Insights, Epidemiology and Market Forecast-2028
1. Cardiotoxicity market report covers a descriptive overview and comprehensive insight of the Cardiotoxicity epidemiology and Cardiotoxicity market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Cardiotoxicity market report provides insights on the current and emerging therapies.
3. Cardiotoxicity market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Cardiotoxicity market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cardiotoxicity market.
Request for sample pages
"There are atleast 9 classes of current cancer therapy agents causing distinct patterns of cardiotoxicity- Type I: Anthracyclines; Type II: HER2 inhibitors; Type III: Vascular endothelial growth factor (VEGF) inhibitors; Type IV: Bcr-Abl inhibitors; Type V: 5-FU and 5-FU metabolites; Type VI: Checkpoint inhibitors; Type VII: Proteosome inhibitors; Type VIII: Histone deacetylase inhibitors; Type IX: Bruton's tyrosine kinase inhibitors etc."
The administration of anthracyclines as infusions rather than as boluses or the liposomal encapsulation of doxorubicin are all measures which may help to reduce cardiac toxicity. Dexrazoxane, an EDTA like chelator, may reduce the risk of Cardiotoxicity in association with doxorubicin or epirubicin. It has been shown to interfere with iron-dependent redox reactions, thereby reducing ROS originating from DOX. Dexrazoxane also directly inhibits topoisomerase II?, thus preventing anthracycline binding and DNA double-strand breaks. However, the ability of Dexrazoxane in reducing anthracycline-induced Cardiotoxicity has been limited in its clinical use because of adverse side effects.
On the other hand, carvedilol, a beta-blocker with antioxidant properties, might reduce the risk of anthracyclines induced Cardiotoxicity. The initiation of standard heart failure treatment, as well as the discontinuation of the cardiotoxic agent, will increase the recovery of left ventricular function. Various research is ongoing to establish the diagnostic test for Cardiotoxicity, once the diagnosis of chemotherapy-induced Cardiotoxicity is established, the oncologist and cardiologist discuss the patient's prognosis while weighing the risks of discontinuing the cardiotoxic agent.
AstraZeneca conducted a study to find the effect of the angiotensin-II-receptor (AT1) blocker Candesartan, to check whether it can prevent or ameliorate trastuzumab-related cardiotoxic effects, however, the findings did not support the hypothesis of concomitant use of candesartan that it protects against a decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer.
Due to unavailability of approved therapies and lack of emerging therapies, there is currently a high unmet need of research and extensive, multi-centre trials are needed to establish guidelines for chemotherapy-induced Cardiotoxicity. Anticancer drug?induced toxicities occur due to the agents that are not selective, or the targets are not distinctive to cancer cells. The research gaps emanating from the problematic specificity/selectivity of drugs, lead to a stoppage on effective clinical management (curative care). It is because of uncontrollable toxicities on multiple organs. By making better specificity/selectivity of drug target selection (druggable molecular targets and tumour-specific antigens), it is considered the most critical factor, and this strategy will substantially minimize the risk of potential cardiovascular safety liabilities and other organ toxicities. The pharmaceutical industry may head towards more selective agents to meet current clinical challenges. Overall, the rising incident population, technological advancements, identification of biomarkers for the diagnosis may drive the clinical trials, development of emerging therapies and the overall market of Cardiotoxicity during the forecast period [2019-2028].
Table of contents
1. Report Introduction
2. Cardiotoxicity Market Overview at a Glance
3. Cardiotoxicity Disease Background and Overview
4. Cardiotoxicity Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Incident cases of Cardiotoxicity (2017-2028)
4.3. Gender-Specific cases of Cardiotoxicity (2017-2028)
4.4. Age-Specific cases of Cardiotoxicity (2017-2028)
4.5. Diagnosed and Treatable cases of Cardiotoxicity (2017-2028)
4.6. Cardiotoxicity Country- Wise Epidemiology
4.7. United States
4.9. Assumptions and Rationale
4.14. United Kingdom
5. Cardiotoxicity Treatments Medical Practices
6. Cardiotoxicity Marketed Therapies
6.1. ZINECARD: Pfizer
7. Cardiotoxicity Market Size
8. 7MM Cardiotoxicity: Country-Wise Market Analysis
9. United States Market Size
10. Germany Market Size
11. France Market Size
12. United Kingdom Market Size
13. Spain Market Size
14. Italy Market Size
15. Japan Market Size
16. Cardiotoxicity Report Methodology
17. DelveInsight Capabilities
19. About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.